Written by: marc

Tagworks@NanoCity 2014

Tagworks will participate in NanoCity 2014, October 27-28 in Utrecht, The Netherlands. More on the event: www.nanocity2014.com  
September 5, 2014

Tagworks@NCI IMAT Principal Investigator’s meeting

Tagworks will participate in the US National Cancer Institute's IMAT (Innovative Molecular Analysis Technologies) Principal Investigator's meeting on 12-13 November 2014 in Bethesda.
July 25, 2014

Tagworks@World ADC Mastermind

Tagworks has been invited to participate in the World ADC Mastermind session on 26 August 2014 in Cambridge, UK  
July 25, 2014

World ADC Frankfurt 2015

World ADC, 23-25 February 2015, Frankfurt, Germany More on the conference: adcsummit-europe.com
July 10, 2014

World ADC San Diego

World ADC, 26-29 October 2014, San Diego More on the conference: adc-summit.com
July 10, 2014

WMIC 2014

World Molecular Imaging Congress, 17-20 September 2014, Seoul, Korea More on the conference: www.wmis.org
July 10, 2014

Tagworks presents at Gordon Research Conference

Marc Robillard, CEO of Tagworks Pharmaceuticals has been invited to speak during the Gordon Research Conference on Organic Reactions and Processes, held from 13-18 July 2014 at Bryant University, Smithfield, RI. In his lecture entitled "In vivo Chemistry for Cancer Imaging and Therapy" Marc Robillard will present the company's R&D …
July 7, 2014

Tagworks and the University of Missouri-Columbia receive $ 585k NIH grant

Together with prof. Tom Quinn of the University of Missouri-Columbia, Tagworks succeeded in securing an Exploratory/Development grant from the US National Institutes of Health (NIH) Innovative Molecular Analysis Technologies (IMAT) program for the project "In vivo metal-free cycloaddition chemistry driven pretargeted cancer radiotherapy". The proposal was ranked in the top …
December 16, 2013

Click to release – Tagworks publishes new approach to selective bioorthogonal release

By modifying the fastest and highly selective click reaction, the inverse-electron-demand-Diels-Alder reaction, Tagworks has achieved selective bioorthogonal release. This holds promise for the chemically triggered release, and thus activation, of drugs from tumor-bound Antibody-Drug Conjugates (ADCs), which would greatly enhance the scope of suitable ADC targets. Published in: Angewandte Chemie …
November 26, 2013

Tagworks paper in Journal Nuclear Medicine

Tagworks' pretargeting technology can boost tumor/non-tumor ratios compared with conventional radioimmunoimaging and -therapy. Published in Journal Nuclear Medicine 2013, 54, 11, 1989-1995 doi:10.2967/jnumed.113.12.3745
October 7, 2013

Curious about what we do? Get in touch!

Logo-diap

About    Our Technology   Pipeline    Join us    News    Contact

Contact
T +31 85 800 8550
info@tagworkspharma.com

Address
Tagworks Pharmaceuticals BV
Toernooiveld 1
6525 ED  Nijmegen
The Netherlands

Stay updated

© Tagworks Pharmaceuticals, 2024 | Terms of use | Design by Ape to Zebra